SC2.0 More Details »
Click for More...
As one of the world's leading biotech companys, GenScript has established a comprehensive drug development platform to integrate antibody engineering and antibody production technologies. Our scientists, with extensive experience in antibody drug development, provide superior services such as antibody humanization and antibody sequencing.
See more »
The biopharmaceuticals market in the U.S. is expected to increase to $144 billion by 2016, with an annual growth rate of 11.2%. Monoclonal antibody (mAbs) drugs represent a primary sector of the biopharmaceuticals market. The specificity of mAbs has tremendous clinical value, making them highly effective therapeutic agents. Many large pharmaceutical companies are increasing their investment in mAb research after the success of drugs such as Remicade™ and Rituxan™.
Our fast turnaround ensures that your antibody project stays on track.
Our service reduces human immunogenicity while maintaining target affinity.
GenScript can generate therapeutic antibody candidates for your drug discovery.
Our experienced scientists provide accuate analysis using state of the art technology.
We offer comprehensive assays to determine the mechanisms of your antibody and antigen.
We can determine the PK/PD profile of your antibody therapeutic with our efficacy and safety models.
A fast and inexpensive approach for generating therapeutic antibodies.
We provide fast turnaround and the flexibility of choosing the expression system.
We can generate up to 50mg of antibody in as few as 8-12 weeks.
We provide up to 100 high quality hybridomas to ensure success.
We offer production and industrial grade stable cell lines with MTX amplification and screening.
Our experienced scientists can scale-up antibody production by maximizing expression and purity.
Please contact us if you need immediate assistance.
Please contact us (phone: 1-877-436-7274 or email: email@example.com),if you need immediate assistance.